Rafarma Pharmaceuticals Inc (RAFA)
OTHER OTC:RAFA
Total Valuation
Rafarma Pharmaceuticals has a market cap or net worth of $5.59M. The enterprise value is $5.19M.
Market Cap$5.59M
Enterprise Value$5.19M
Share Statistics
Rafarma Pharmaceuticals has 93,167,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding93,167,000
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Rafarma Pharmaceuticals’s return on equity (ROE) is 0.03 and return on invested capital (ROIC) is 3.80%.
Return on Equity (ROE)0.03
Return on Assets (ROA)0.03
Return on Invested Capital (ROIC)3.80%
Return on Capital Employed (ROCE)0.05
Revenue Per Employee13.11K
Profits Per Employee498.57
Employee Count700
Asset Turnover0.77
Inventory Turnover53.27
Valuation Ratios
The current PE Ratio of Rafarma Pharmaceuticals is 23.8. Rafarma Pharmaceuticals’s PEG ratio is 0.21.
PE Ratio23.8
PS Ratio0.26
PB Ratio0.23
Price to Fair Value0.23
Price to FCF-150.44
Price to Operating Cash Flow79.79
PEG Ratio0.21
Income Statement
In the last 12 months, Rafarma Pharmaceuticals had revenue of 9.18M and earned 349.00K in profits. Earnings per share was <0.01.
Revenue9.18M
Gross Profit761.00K
Operating Income489.00K
Pretax Income427.00K
Net Income349.00K
EBITDA489.00K
Earnings Per Share (EPS)<0.01
Cash Flow
In the last 12 months, operating cash flow was -137.00K and capital expenditures -724.00K, giving a free cash flow of -861.00K billion.
Operating Cash Flow-137.00K
Free Cash Flow-861.00K
Free Cash Flow per Share>-0.01
Dividends & Yields
Rafarma Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-0.35
52-Week Price Change-26.83%
50-Day Moving Average0.06
200-Day Moving Average0.05
Relative Strength Index (RSI)50.71
Average Volume (3m)16.93K
Important Dates
Rafarma Pharmaceuticals upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
Rafarma Pharmaceuticals as a current ratio of 1.13, with Debt / Equity ratio of 0.00%
Current Ratio1.13
Quick Ratio1.03
Debt to Market Cap<0.01
Net Debt to EBITDA-0.07
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Rafarma Pharmaceuticals has paid 78.00K in taxes.
Income Tax78.00K
Effective Tax Rate0.18
Enterprise Valuation
Rafarma Pharmaceuticals EV to EBITDA ratio is 4.85, with an EV/FCF ratio of -148.25.
EV to Sales0.26
EV to EBITDA4.85
EV to Free Cash Flow-148.25
EV to Operating Cash Flow21.18
Balance Sheet
Rafarma Pharmaceuticals has $77.00K in cash and marketable securities with $0.00 in debt, giving a net cash position of $77.00K billion.
Cash & Marketable Securities$77.00K
Total Debt$0.00
Net Cash$77.00K
Net Cash Per Share<$0.01
Tangible Book Value Per Share$0.12
Margins
Gross margin is 6.37%, with operating margin of 5.33%, and net profit margin of 3.80%.
Gross Margin6.37%
Operating Margin5.33%
Pretax Margin4.65%
Net Profit Margin3.80%
EBITDA Margin5.33%
EBIT Margin5.33%
Analyst Forecast
The average price target for Rafarma Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―